NRX Pharmaceuticals Inc (NRXP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NRX Pharmaceuticals Inc (NRXP) has a cash flow conversion efficiency ratio of 0.112x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.89 Million) by net assets ($-25.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NRXP defensive interval ratio to measure how many days the company can operate on defensive assets alone.
NRX Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how NRX Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NRX Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NRX Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NewFlex Technology Co. Ltd
KQ:085670
|
0.010x |
|
An-Shin Food Services Co Ltd
TWO:1259
|
0.060x |
|
Perak Transit Bhd
KLSE:0186
|
0.052x |
|
Scorpio Gold Corp
V:SGN
|
-0.081x |
|
Rottneros AB
ST:RROS
|
-0.028x |
|
U-Media Communications
TWO:6470
|
0.100x |
|
Pamel Yenilenebilir Elektrik Uretim AS
IS:PAMEL
|
-0.009x |
|
Shan-Loong Transportation Co Ltd
TW:2616
|
-0.011x |
Annual Cash Flow Conversion Efficiency for NRX Pharmaceuticals Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of NRX Pharmaceuticals Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see NRXP company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-23.22 Million | $-10.64 Million | 0.458x | -75.19% |
| 2023-12-31 | $-11.73 Million | $-21.66 Million | 1.846x | +134.40% |
| 2022-12-31 | $7.41 Million | $-39.76 Million | -5.366x | -196.10% |
| 2021-12-31 | $20.81 Million | $-37.70 Million | -1.812x | -3601.91% |
| 2020-12-31 | $-43.77 Million | $-2.27 Million | 0.052x | +292.57% |
| 2019-12-31 | $29.50 Million | $-792.73K | -0.027x | -294.90% |
| 2018-12-31 | $69.54 Million | $-473.19K | -0.007x | -248.09% |
| 2017-12-31 | $69.47 Million | $-135.81K | -0.002x | -- |
About NRX Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in p… Read more